Everett Moding, MD, PhD

#PhysicianScientist @StanfordRadOnc studying #radiationbiology and #cancerevolution using #ctDNA and #GEMMs

[Everett Moding, MD, PhD @everettmoding]

Soft tissue sarcomas (#STS) have few recurrent mutations, making ctDNA testing a challenge. In our new paper in @JCO_ASCO, we show that personalized ctDNA analysis achieves high detection rates and can track treatment response in localized STS. 🧵 (1/11)
https://t.co/J3tUxBrFWT

[Everett Moding, MD, PhD @everettmoding]

@philippewilli @JCO_ASCO We only monitored SNVs in this study, and ctDNA cleared after resection in all patients with dedifferentiated liposarcoma.

[Everett Moding, MD, PhD @everettmoding]

Soft tissue sarcomas (#STS) have few recurrent mutations, making ctDNA testing a challenge. In our new paper in @JCO_ASCO, we show that personalized ctDNA analysis achieves high detection rates and can track treatment response in localized STS. 🧵 (1/11)
https://t.co/J3tUxBrFWT

[Anthony T. Nguyen, MD, PhD @AnthonyNguyenMD]

2nd Annual @RRS_RadRes-@sitcancer Joint Session drew a standing room crowd! Spoke on "Immunological Modulation by Radiation" w/ @everettmoding on the dual, context-dependent role of inflammatory TME in sarcoma vs TNBC/prostate. Thx to @DemariaLab_WCM & @HenningWillers for invite.

[Everett Moding, MD, PhD @everettmoding]

@philippewilli @JCO_ASCO We detected ctDNA pre-treatment in 4 out of 5 patients with dedifferentiated liposarcoma (80%). The numbers are small, but this is similar to the full cohort.

[Stand Up To Cancer @SU2C]

Several years ago, Rob Preece, a long-time marathon runner, developed a soreness in his leg that wasn’t going away. Eventually, a lump appeared in the same spot. A biopsy revealed something he never could have expected: a rare and aggressive form of sarcoma called UPS.

Rob’s doctor, @AngelaHong of @Sydney_Uni, told him about a clinical trial supported by #StandUpToCancer and led by @DrDavidKirsch and @EverettModing that was testing a new treatment approach for UPS. Rob enrolled in the trial and now, more than 2 years later, he is cancer-free and enjoying life, including frequent outings with his granddaughter to get ice cream. “This trial was life saving for me.” ❤️

The results of this SU2C-funded clinical trial represented the first significant improvement in the treatment of this form of sarcoma in decades. Learn more about Rob’s story and this cancer research breakthrough at https://t.co/Hnv7FEYcgW.

[Henning Willers, MD, FASTRO @HenningWillers]

Grateful for 2nd Joint @sitcancer & @RRS_RadRes Symposium at #RadRes2026 on radiation/immunology topics, how radiation shapes the anti-tunor response☢️

Inspiring correlative science talks from @everettmoding & @AnthonyNguyenMD + 3 oral abstract talks🙏🙏🙏

Looking forward to more collaborations between our Societies 👍

[Marina Francis, PhD @marinafrancis7]

Despite the Nor'Easter crashing #ASTRO26's party, it's a pleasure to make it to the comprehensive #RadOnc annual meeting for the 3rd year in a row, and present my work in the Moding Lab!

P.S. I hope the organizing team considers #SanDiego for upcoming meetings ☀️😅

[Journal of Clinical Oncology @JCO_ASCO]

Now out in #JCO 👇

Personalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 Trial. Co-authored by @everettmoding.

Read the article: https://t.co/adQDxoC1FX

[Stanford Radiation Oncology @StanfordRadOnc]

Please join us in congratulating @everettmoding, MD, PhD, for receiving the @RRS_RadRes Scholar-in-Training Excellence in Mentorship award! This award honors an individual who has provided exceptional mentoring to a Scholar-in-Training member. Congratulations!

[Journal of Clinical Oncology @JCO_ASCO]

Personalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 Trial. Co-authored by @everettmoding.

Read the full article. https://t.co/yJNgDYJgGn

[Everett Moding, MD, PhD @everettmoding]

@SprakerMDPhD I think so!

[Everett Moding, MD, PhD @everettmoding]

@aadel_chaudhuri @JCO_ASCO Thank you, @aadel_chaudhuri!

[Everett Moding, MD, PhD @everettmoding]

Thank you to @SARCtrials for sponsoring and conducting this trial at 20 sites around the world. This work was supported by a @SU2C Catalyst Grant with support from @Merck, @theNCI, and the DoD. Finally, we are grateful to patients and their caregivers for participating. (11/11)

[Everett Moding, MD, PhD @everettmoding]

Grateful to @DKirschMDPhD, @YvonneMowery, @richardriedelmd, and Brian Brigman for leading a hugely impactful trial with rich correlative samples. Thank you to all our co-authors for making this possible! @ShaghayeghSoudi, @SiyerRoohani, @AngelaHong, @MattRijn (10/11)